Search research articles
Contact Us
Filters
Showing results (51-60 of 70) with videos related to
Page
of 7
Sort By:
Breast Cancer Research and Treatment
|
December 2, 2021
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing
Phuong Dinh, J Dinny Graham, Elisabeth N Elder, et al.
JCO Precision Oncology
|
February 9, 2022
<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition
Tania Moujaber, Dariush Etemadmoghadam, Catherine J Kennedy, et al.
Scientific Reports
|
January 26, 2018
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Bo Gao, Yi Lu, Annemieke J M Nieuweboer, et al.
Cancer Research
|
August 17, 2012
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin
Prue A Cowin, Joshy George, Sian Fereday, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver
Catherine Emmanuel, Yoke-Eng Chiew, Joshy George, et al.
Cancer Research
|
June 25, 2017
<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
Dariush Etemadmoghadam, Walid J Azar, Ying Lei, et al.
The Journal of Clinical Investigation
|
October 29, 2024
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Brad H Nelson, Phineas Hamilton, Minh Tung Phung, et al.
The Journal of Pathology
|
December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas
Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 27, 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Nicola S Meagher, Linyuan Wang, Peter F Rambau, et al.
Mayo Clinic Proceedings
|
March 6, 2018
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
Matthew S Block, Robert A Vierkant, Peter F Rambau, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 70) with videos related to
Sort By:
Page
of 7
Breast Cancer Research and Treatment
|
December 2, 2021
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing
Phuong Dinh, J Dinny Graham, Elisabeth N Elder, et al.
JCO Precision Oncology
|
February 9, 2022
<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition
Tania Moujaber, Dariush Etemadmoghadam, Catherine J Kennedy, et al.
Scientific Reports
|
January 26, 2018
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Bo Gao, Yi Lu, Annemieke J M Nieuweboer, et al.
Cancer Research
|
August 17, 2012
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin
Prue A Cowin, Joshy George, Sian Fereday, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver
Catherine Emmanuel, Yoke-Eng Chiew, Joshy George, et al.
Cancer Research
|
June 25, 2017
<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
Dariush Etemadmoghadam, Walid J Azar, Ying Lei, et al.
The Journal of Clinical Investigation
|
October 29, 2024
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Brad H Nelson, Phineas Hamilton, Minh Tung Phung, et al.
The Journal of Pathology
|
December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas
Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 27, 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Nicola S Meagher, Linyuan Wang, Peter F Rambau, et al.
Mayo Clinic Proceedings
|
March 6, 2018
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
Matthew S Block, Robert A Vierkant, Peter F Rambau, et al.
Page
of 7